01698nas a2200301   4500000000100000008004100001260002500042653001100067653001600078653001200094100001500106700001300121700001600134700001600150700001800166700001500184700001400199700001500213700001500228700001500243700001300258245008900271856026000360300001000620490000700630520074500637022001401382       2026                            d  c03/2026bElsevier BV10aHTLV-110aCoinfection10aLeprosy1 aFaria LGAP1 aMoura MN1 ada Cruz ALB1 aAndrade FDO1 aCerqueira APN1 aCariús LF1 aNovaes AF1 aRibeiro SO1 aTakenami I1 aBarreto FK1 aCosta DT00aType 1 leprosy reaction in a patient coinfected with HTLV-1 and Mycobacterium leprae  uhttps://pdf.sciencedirectassets.com/271317/1-s2.0-S0196439925X00076/1-s2.0-S0196439925000704/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEKj%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJHMEUCIB5huC9n%2FtsS2mXGsMnw2HzCeTtIHRF3ndtjjfTx1hSnAiEAmcdQ%2FicF  a14-170 v543 a<p>Coinfection with HTLV-1 and&nbsp;<em>Mycobacterium leprae</em>&nbsp;can present significant clinical challenges due to their complex interactions. The chronic immune activation induced by HTLV-1 can potentiate leprosy-related neurological symptoms, complicating treatment. This report describes a 61-year-old man from a Brazilian endemic area for HTLV-1 and leprosy, who was diagnosed with both infections and developed a type 1 leprosy reaction. The patient presents a significant exacerbation of neurological symptoms, with sensory and motor impairments across multiple limbs. Routine screening for HTLV-1 in patients diagnosed with leprosy, especially in endemic areas, is essential for better clinical management and prognosis.</p>
  a0196-4399